National Health (Supply of Pharmaceutical Benefits—Under Co-payment Data and Claims for Payment) Rules 2022
13Procedures for making payments in respect of claims
Start here
Get a plain-English read of 13
Turn the raw legal text into a practical explanation grounded in National Health (Supply of Pharmaceutical Benefits—Under Co-payment Data and Claims for Payment) Rules 2022.
13 Procedures for making payments in respect of claims
(1) For the purposes of subparagraph 99AAA(8)(e)(ii) of the Act, this section defines the procedures to be followed by the Chief Executive Medicare, on behalf of the Secretary, in making payments in respect of claims by an approved supplier in relation to the supply of pharmaceutical benefits. (2) The Chief Executive Medicare must ensure that: (a) payments are made by: (i) an electronic funds transfer from the Commonwealth to the account at a financial institution nominated in writing by the approved supplier; or (ii) any other form of electronic payment from the Commonwealth to the approved supplier nominated in writing by the approved supplier; and (b) a statement of account is given to the approved supplier in respect of each claim for payment.
Note: Example: For the purposes of subparagraph (a)(ii), other forms of electronic payment include PayID and payments through mobile telephone applications.
(3) Information included in a statement of account about ACSS payments made in respect of ACSS eligible supplies made before 1 July 2025: (a) is not required to relate to a particular claim period; and (b) may be included in a statement of account that relates to supplies of pharmaceutical benefits made in different claim periods.
Note: Approved pharmacists are the only approved suppliers who are entitled to ACSS payments – see section 99AAAA of the Act.